Ifngtm1.1(KOMP)Vlcg/Ifng+
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/Ucd
|
abnormal lung morphology |
J:211773
|
decreased prepulse inhibition |
J:211773
|
increased hematocrit |
J:211773
|
Ifngtm1.1(KOMP)Vlcg/Ifngtm1.1(KOMP)Vlcg
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/MbpMmucd
|
embryonic lethality prior to organogenesis |
J:211773
|
embryonic lethality prior to tooth bud stage |
J:211773
|
Ifngtm1.1(KOMP)Vlcg/Ifngtm1.1(KOMP)Vlcg
C57BL/6N-Ifngtm1.1(KOMP)Vlcg/Ucd
|
preweaning lethality, complete penetrance |
J:211773
|
Ifngtm1.1Hayg/Ifngtm1.1Hayg
Not Specified
|
abnormal B cell differentiation |
J:220784
|
abnormal bone marrow cell morphology/development |
J:220784
|
abnormal circulating cytokine level |
J:220784
|
abnormal cytokine level |
J:220784
|
abnormal erythropoiesis |
J:220784
|
abnormal hematopoietic stem cell morphology |
J:220784
|
abnormal lymph node morphology |
J:220784
|
abnormal proerythroblast morphology |
J:220784
|
abnormal T cell activation |
J:220784
|
anemia |
J:220784
|
decreased bone marrow cell number |
J:220784
|
decreased common myeloid progenitor cell number |
J:220784
|
decreased erythrocyte cell number |
J:220784
|
decreased erythroid progenitor cell number |
J:220784
|
decreased granulocyte monocyte progenitor cell number |
J:220784
|
decreased leukocyte cell number |
J:220784
|
decreased mature B cell number |
J:220784
|
decreased megakaryocyte cell number |
J:220784
|
decreased megakaryocyte-erythroid progenitor cell number |
J:220784
|
decreased myeloid cell number in bone marrow |
J:220784
|
decreased pre-B cell number |
J:220784
|
impaired hematopoiesis |
J:220784
|
increased erythroblast number |
J:220784
|
increased hematopoietic stem cell number |
J:220784
|
increased nucleated erythrocyte cell number |
J:220784
|
increased T cell number |
J:220784
|
pancytopenia |
J:220784
|
spleen atrophy |
J:220784
|
thrombocytopenia |
J:220784
|
thymus atrophy |
J:220784
|
Ifngtm1Lky/Ifngtm1Lky
involves: 129S4/SvJae * C57BL/6
|
normal
immune system phenotype |
J:189794
|
Ifngtm1Ts/Ifngtm1Ts
B6.129S7-Ifngtm1Ts
|
abnormal B cell physiology |
J:112084
|
abnormal cytokine secretion |
J:18801,
J:110826
|
abnormal immunoglobulin level |
J:18801
|
abnormal lymph node cell ratio |
J:112084
|
abnormal response to infection |
J:18801,
J:110826
|
abnormal response to transplant |
J:42090
|
decreased IgG2a level |
J:18801
|
decreased IgG3 level |
J:18801
|
decreased tumor latency |
J:77491
|
increased CD8-positive, alpha-beta T cell number |
J:112048
|
increased IgE level |
J:18801
|
increased IgG1 level |
J:18801,
J:112048
|
increased interleukin-2 secretion |
J:112048
|
increased interleukin-5 secretion |
J:112048
|
increased interleukin-10 secretion |
J:112048
|
increased lymphoma incidence |
J:77491
|
increased sarcoma incidence |
J:77491
|
increased susceptibility to Coronaviridae infection |
J:112048
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality |
J:112048
|
increased susceptibility to parasitic infection |
J:18801
|
increased susceptibility to parasitic infection induced morbidity/mortality |
J:18801,
J:110826
|
increased T cell derived lymphoma incidence |
J:77491
|
premature death |
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
B6.129S7-Ifngtm1Ts/J
|
abnormal circulating cytokine level |
J:47459
|
abnormal cytokine secretion |
J:120556
|
abnormal dendritic cell antigen presentation |
J:134949
|
abnormal dendritic cell chemotaxis |
J:134949
|
abnormal dendritic cell physiology |
J:134949
|
abnormal humoral immune response |
J:45665
|
abnormal immune tolerance |
J:45665
|
abnormal immunoglobulin level |
J:45665
|
abnormal Langerhans cell physiology |
J:134949
|
abnormal macrophage chemotaxis |
J:136628
|
abnormal nitric oxide homeostasis |
J:122801
|
abnormal redox activity |
J:122801
|
abnormal response to injury |
J:136628
|
abnormal response to new environment |
J:54250
|
abnormal spleen morphology |
J:47459
|
abnormal spleen red pulp morphology |
J:47459
|
abnormal spleen white pulp morphology |
J:47459
|
abnormal type IV hypersensitivity reaction |
J:45665
|
abnormal urine homeostasis |
J:118730
|
albuminuria |
J:118730
|
decreased interferon-gamma secretion |
J:120556
|
decreased interleukin-10 secretion |
J:120556,
J:134949
|
decreased length of allograft survival |
J:44346
|
decreased susceptibility to injury |
J:108148
|
decreased vertical activity |
J:54250
|
enlarged mesenteric lymph nodes |
J:50832
|
enlarged spleen |
J:47459
|
extramedullary hematopoiesis |
J:47459
|
glomerulonephritis |
J:118730
|
normal
immune system phenotype |
J:114783
|
impaired skeletal muscle regeneration |
J:136628
|
increased circulating interleukin-6 level |
J:47459
|
increased fear-related response |
J:54250
|
increased granulocyte number |
J:47459
|
increased interleukin-4 secretion |
J:120556
|
increased interleukin-12 secretion |
J:134949
|
increased leukocyte cell number |
J:47459
|
increased monocyte cell number |
J:47459
|
increased NK T cell number |
J:122801
|
increased susceptibility to bacterial infection |
J:47459
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:47459
|
increased susceptibility to parasitic infection |
J:50832
|
increased susceptibility to parasitic infection induced morbidity/mortality |
J:50832
|
increased susceptibility to type IV hypersensitivity reaction |
J:118730
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:91927
|
pale spleen |
J:47459
|
skeletal muscle fibrosis |
J:136628
|
stomach inflammation |
J:120556
|
Ifngtm1Ts/Ifngtm1Ts
C.129S7(B6)-Ifngtm1Ts/J
|
abnormal adaptive immunity |
J:115144
|
abnormal circulating cytokine level |
J:47459
|
abnormal cytokine secretion |
J:115144
|
abnormal cytotoxic T cell physiology |
J:115144
|
abnormal inflammatory response |
J:115144
|
abnormal macrophage physiology |
J:115144
|
abnormal maternal decidual layer morphology |
J:56503
|
abnormal NK cell physiology |
J:115144
|
abnormal response to new environment |
J:54250
|
abnormal spleen morphology |
J:115144
|
abnormal spleen red pulp morphology |
J:47459
|
abnormal spleen white pulp morphology |
J:47459
|
abnormal tumor pathology |
J:115144
|
abnormal uterine NK cell morphology |
J:56503
|
abnormal uterine NK cell physiology |
J:56503
|
decreased litter size |
J:56503
|
decreased susceptibility to parasitic infection |
J:50832
|
decreased tumor latency |
J:115144
|
decreased vertical activity |
J:54250
|
enlarged spleen |
J:47459
|
extramedullary hematopoiesis |
J:47459
|
increased circulating interleukin-6 level |
J:47459
|
increased fear-related response |
J:54250
|
increased granulocyte number |
J:47459
|
increased leukocyte cell number |
J:47459
|
increased monocyte cell number |
J:47459
|
increased susceptibility to bacterial infection |
J:47459
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:47459
|
increased uterine NK cell number |
J:56503
|
pale spleen |
J:47459
|
Ifngtm1Ts/Ifngtm1Ts
C.129S7-Ifngtm1Ts
|
abnormal cytokine secretion |
J:110826
|
abnormal humoral immune response |
J:45665
|
abnormal immune tolerance |
J:45665
|
abnormal immunoglobulin level |
J:45665
|
abnormal response to infection |
J:110826
|
increased interleukin-5 secretion |
J:110826
|
increased lung adenocarcinoma incidence |
J:77491
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:83180
|
increased susceptibility to experimental autoimmune encephalomyelitis |
J:34161
|
increased susceptibility to parasitic infection |
J:110826
|
increased susceptibility to parasitic infection induced morbidity/mortality |
J:110826
|
increased tumor latency |
J:77491
|
normal
neoplasm |
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd
|
abnormal cytokine level |
J:112600
|
abnormal immunoglobulin level |
J:29170
|
abnormal response to infection |
J:29170,
J:110721
|
corneal vascularization |
J:114973
|
decreased susceptibility to type IV hypersensitivity reaction |
J:29170
|
impaired natural killer cell mediated cytotoxicity |
J:73948
|
increased IgG1 level |
J:110721
|
increased interleukin-17 secretion |
J:132905
|
increased susceptibility to bacterial infection |
J:110856
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:110856
|
increased susceptibility to Herpesvirales infection |
J:29170
|
increased susceptibility to Herpesvirales infection induced morbidity/mortality |
J:29170
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss
|
decreased IgG2a level |
J:119207
|
decreased IgG level |
J:119207
|
decreased physiological sensitivity to xenobiotic |
J:119207
|
decreased susceptibility to autoimmune disorder |
J:119207
|
increased IgG1 level |
J:119207
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * BALB/c
|
abnormal susceptibility to infection |
J:39478
|
decreased airway responsiveness |
J:114213
|
decreased IgE level |
J:114213
|
decreased inflammatory response |
J:114213
|
normal
immune system phenotype |
J:39881
|
increased airway responsiveness |
J:114213
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal macrophage physiology |
J:66802
|
abnormal MHC II cell surface expression on macrophages |
J:66802
|
abnormal NK cell physiology |
J:66802,
J:115033
|
abnormal skin physiology |
J:55740
|
abnormal type IV hypersensitivity reaction |
J:55740
|
alveolar process atrophy |
J:147935
|
decreased length of allograft survival |
J:44346
|
decreased susceptibility to parasitic infection |
J:189794
|
decreased susceptibility to parasitic infection induced morbidity/mortality |
J:189794
|
decreased tumor incidence |
J:138466
|
normal
immune system phenotype |
J:119206
|
increased metastatic potential |
J:152785
|
increased splenocyte proliferation |
J:66802
|
increased susceptibility to bacterial infection |
J:66802
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * C57BL/6J
|
increased susceptibility to bacterial infection |
J:15723
|
increased susceptibility to bacterial infection induced morbidity/mortality |
J:15723
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp
|
decreased anti-double stranded DNA antibody level |
J:39600
|
decreased anti-nuclear antigen antibody level |
J:39600
|
decreased autoantibody level |
J:39600
|
decreased IgA level |
J:39600
|
decreased IgG2a level |
J:39600
|
decreased IgG2b level |
J:39600
|
decreased IgG3 level |
J:39600
|
decreased IgM level |
J:39600
|
decreased immunoglobulin level |
J:39600
|
decreased susceptibility to autoimmune disorder |
J:39600
|
Ifngtm1Ts/Ifngtm1Ts
involves: 129S7/SvEvBrd * NOD
|
normal
immune system phenotype |
J:33427
|
Ifngtm1Ts/Ifngtm1Ts
NOD.129S7(B6)-Ifngtm1Ts/DvsJ
|
abnormal cytotoxic T cell physiology |
J:72818
|
abnormal diapedesis |
J:72818
|
abnormal pancreatic beta cell physiology |
J:72818
|
decreased susceptibility to autoimmune diabetes |
J:72818
|
Ifngtm1Ts/Ifngtm1Ts
NOD.129S7-Ifngtm1Ts
|
abnormal susceptibility to autoimmune disorder |
J:33427
|
decreased susceptibility to autoimmune diabetes |
J:95105
|
Ifngtm1Ts/Ifngtm1Ts
NOD.Cg-Ifngtm1Ts Prkdcscid
|
decreased susceptibility to autoimmune diabetes |
J:72818
|
Ifngtm1Yiw/Ifngtm1Yiw
B6.129X1-Ifngtm1Yiw
|
abnormal abdominal wall morphology |
J:50405
|
abnormal behavior |
J:50405
|
abnormal circulating interferon level |
J:91691
|
abnormal liver morphology |
J:50405
|
abnormal thoracic cavity morphology |
J:50405
|
ascites |
J:50405
|
focal hepatic necrosis |
J:91691
|
increased susceptibility to Coronaviridae infection |
J:50405,
J:91691
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality |
J:50405,
J:91691
|
liver inflammation |
J:50405
|
peritoneal inflammation |
J:50405
|
Ifngtm1Yiw/Ifngtm1Yiw
C.129X1-Ifngtm1Yiw
|
abnormal circulating interferon level |
J:91691
|
diffuse hepatic necrosis |
J:91691
|
increased circulating alanine transaminase level |
J:91691
|
increased susceptibility to Coronaviridae infection |
J:91691
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality |
J:91691
|
Ifngtm1Yiw/Ifngtm1Yiw
involves: 129X1/SvJ * C57BL/6
|
abnormal female reproductive system physiology |
J:59892
|
decreased apoptosis |
J:41632
|
decreased inflammatory response |
J:41632,
J:88226
|
hepatic necrosis |
J:41632
|
Ifngtm3.1Lky/Ifngtm3.1Lky
B6.129S4-Ifngtm3.1Lky
|
no abnormal phenotype detected |
J:183078
|
Ifngtm3.1Lky/Ifngtm3.1Lky
C.129S4-Ifngtm3.1Lky
|
no abnormal phenotype detected |
J:183078
|